DEANNA WEIBEL: Open Payments
NPI 1417071747 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,272 in 97 payments from 17 companies in 2025. Trend: 2023 $1,927 · 2024 $1,425 · 2025 $2,272
Food & beverage: $2,223Education: $49
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 14 | $417 |
| GlaxoSmithKline, LLC. | 15 | $241 |
| GENZYME CORPORATION | 10 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $200 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $181 |
| CSL Behring | 7 | $177 |
| AstraZeneca Pharmaceuticals LP | 7 | $152 |
| Novartis Pharmaceuticals Corporation | 9 | $143 |
| Galderma Laboratories, L.P. | 1 | $136 |
| Amgen Inc. | 4 | $91 |
Products named: DUPIXENT, NEFFY, XOLAIR, TRELEGY ELLIPTA, CUVITRU, NEMLUVIO, FASENRA, NUCALA.
Industry payments across TX — which companies pay providers there.
